-
Austrian Biotech Plans Zika Vaccine Clinical Trials in 12 Months
An Austrian biotech company working with the Institut Pasteur said on Tuesday it planned to start clinical trials with an experimental Zika vaccine in the next 12 months, marking a further acceleration of research in the field.
- Categories
- Health Care
- Region
- Europe & Eurasia
-
Swine Flu Adds to Brazil’s Zika Worries
Brazil, which will host the Olympics beginning Aug. 5, was already beset by economic problems, a political crisis and the Zika outbreak. Now it's experiencing its worst swine flu outbreak since 2009. Dr. Melvin Sanicas, a program officer at the Bill & Melinda Gates Foundation, wonders if this will be the crisis that forces a change to the Olympic schedule.
- Categories
- Health Care
-
Scientists announce important Zika milestone: First vaccine ready for human trials
Pennsylvania vaccine maker Inovio Pharmaceuticals and South Korea’s GeneOne Life Sciences said Monday that they had received approval from U.S. regulators to start testing a DNA vaccine, known as GLS-5700, on humans.
- Categories
- Health Care
-
‘Disease outbreak guarantees’—A proposed mechanism for enhancing public health capacity
The possible path to offering disease outbreak guarantees is an idea being posed by two global health researchers who suggest that a mechanism for establishing such an instrument could be tied to public health investments.
- Categories
- Health Care
-
With Another Pandemic Looming, Let’s Change Perspective
We cannot prevent the emergence of new viruses, according to Dr. Melvin Sanicas, a Global Health Fellow and program officer at the Bill & Melinda Gates Foundation, but we can take measures to prevent small epidemics from becoming big ones, including investing in infrastructures for preparedness.
- Categories
- Health Care
-
Why the Vaccination Supply Chain Needs Reform
I recently returned from a week in Mozambique with a goal of learning about new immunization supply chain models and observing their impact. I also wanted to better understand opportunities and constraints for taking this work to scale -- in Mozambique and across other Gavi-eligible countries.
- Categories
- Health Care
- Region
- Sub-Saharan Africa
- Tags
- supply chains, vaccines
-
Behind the World’s Top Drugmakers’ Approach to Zika Vaccine
What if a drugmaker spent billions of dollars to create a vaccine -- only to find out humans developed natural resistance to the disease before its product is ready?
- Categories
- Health Care
- Region
- Latin America
- Tags
- vaccines
-
For Struggling Pharma Market, Vaccines Offer Path to Revenue
The revenue growth opportunity in vaccines looks far more promising when compared to the overall market for pharmaceuticals. Revenues earned by vaccines manufacturers worldwide reached $27.6 billion in 2015 according to Kalorama Information, up 11% from $24.7 billion in 2014, as sales in all segments expanded (Figure 1). This is, by Kalorama’s estimate, at least five to ten times the revenue growth rate of the overall pharmaceutical market in recent years. The world vaccines market is predicted to increase at a compound annual rate of 7.6% during 2013–2022, reaching $45.1 billion in 2022 as new product introductions continue and usage of current products expands further.
- Categories
- Health Care
- Tags
- vaccines
Subscribe to Our Weekly Newsletter, "NextBillion Notes"
Published each Wednesday, our e-newsletter features NextBillion's latest original articles, along with a selection of news, jobs, bizdev opportunities and events from our recent coverage — and regular conference ticket giveaways.
We respect your privacy. Your information is safe and will never be shared.
Don't miss out. Subscribe today.